Background: Delayed pressure urticaria (DPU) is a rare form of chronic inducible urticaria (CIndU) when it manifests alone. Treatment of DPU is disappointing owing to the lack of response to antihistamines, even when up-dosing. In addition, the absence of randomized clinical trials and the low number of patients included in the studies mean that there is little scientific evidence for the validity of omalizumab in DPU. Objective: Objectives of the study were to perform a real-world study of the effectiveness and safety of omalizumab in DPU patients without chronic spontaneous urticaria or other forms of CIndU and to describe their clinical and diagnostic features. Method: We performed an ambispective observational study of 14 patients with DPU who did not respond to 2 or more second-generation H1-antihistamines in an up-dosing regimen and/or corticosteroids, montelukast, or cyclosporine. Treatment was initiated with omalizumab 300 mg every 4 weeks. We recorded the following: age, time to diagnosis, previous treatment, diagnostic testing (mean time threshold after removing the stimulus and duration of the lesions), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D dimer, total IgE, antithyroid peroxidase (anti-TPO) antibodies, and the Urticaria Control Test (UCT) score before and after the first dose. We evaluated the efficacy of omalizumab according to the Urticaria Control Test score. We analyzed the time to complete or satisfactory response after the first dose (superfast) and its adverse effects. Results: Women accounted for 64.28% patients. The mean age at diagnosis was 43.64 (±13.78) years. The time to diagnosis was 4.53 (±5.54) years. The mean time threshold after removing the stimulus was 4.18 h (±2.75). The mean duration of lesions after testing was 32.42 (±13.8) hours. High ERS values (>20.0 mm/h) were detected in 50% of patients. CRP was >0.5 mg/dL in 42.85% and D dimer levels were high (>500.0 ng/mL) in 3/10 patients. Anti-TPO level was normal in 100% of patients. Total IgE was >100 IU/mL in 6/8 patients. Medium UCT levels before treatment with omalizumab were 3.07 (±2.40), reaching 15.28/16 (±1.72) after the first dose of omalizumab. All 14 patients responded superfast, and none experienced an adverse reaction. Conclusions: Despite the limitation of a low sample size in this real-life study, our findings suggest that omalizumab is a rapid, effective, and safe treatment for patients with DPU refractory to antihistamines in an up-dosing regimen. We recommend omalizumab for patients who do not respond to up-dosing antihistamines and montelukast.

Keywords:
Pressure urticaria omalizumab treatment
1.
Lawlor F, Black AK. Delayed pressure urticaria.
Immunol Allergy Clin North Am
. 2004;24(2):247–58, vi–vii.
2.
Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients.
J Am Acad Dermatol
. 1988;18:1289–98.
3.
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias. The EAACI/GA 2 LEN/EDF/UNEV consensus recommendations 2016 update and revision.
Allergy
. 2016;71(6):780–802.
4.
Kulthanan K, Ungprasert P, Tuchinda P, Chularojanamontri L, Charoenpipatsin N, Maurer M. Delayed pressure urticaria: a systematic review of treatment options.
J Allergy Clin Immunol Pract
. 2020;8(6):2035–49.e5.
5.
Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report.
Allergy
. 2010;65(1):138–9.
6.
Quintero OP, Arrondo AP, Veleiro B. Rapid response to omalizumab in 3 cases of delayed pressure urticaria.
J Allergy Clin Immunol Pract
. 2017;5(1):179–80.
7.
Müller S, Rafei-Shamsabadi D, Technau-Hafsi K, Renzel S, Jakob T. Bullous delayed pressure urticaria responding to omalizumab.
Acta Derm Venereol
. 2016;96(3):416–7.
8.
Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, Gómez Armayones S, Serra-Baldrich E, Spertino J, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
Br J Dermatol
. 2021;184(1):167–8.
9.
Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria.
Int Arch Allergy Immunol
. 2011;154:177–80.
10.
Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
J Dermatol Sci
. 2014;73(1):57–62.
11.
Rodríguez-Rodríguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sanchez-González MJ, Alvarez-Mon M. Successful treatment of severe delayed pressure angio-edema with omalizumab.
Allergol Immunopathol
. 2014;42:78–80.
12.
Geller M. Successful treatment of occupational delayed pressure urticaria and angioedema with omalizumab.
Ann Allergy Asthma Immunol
. 2016;116(1):81–2.
13.
Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients.
Br J Dermatol
. 2016;175:404–6.
14.
Straesser MD, Oliver E, Palacios T, Kyin T, Patrie J, Borish L, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
J Allergy Clin Immunol Pract
. 2018;6(4):1386–8.e1.
15.
Kolkhir P, Altrichter S, Asero R, Daschner A, Ferrer M, Giménez-Arnau A, et al. Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria.
Allergy Asthma Immunol Res
. 2021;13(4):545–59.
16.
Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the use in chronic spontaneous urticaria: when and which.
J Allergy Clin Immunol Pract
. 2021;9(3):1067–78.
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.